EGFR and non-small cell lung carcinoma: Most advanced NSCLC patients with these EGFR mutations respond to treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, erlotinib, afatinib, and osimertinib, with median progression-free survivals (mPFS) of 9.2–18.9 months6–11.